May. 14, 2020—From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic.
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Feb. 8, 2018—Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer.
Mar. 23, 2017—Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.
Nov. 17, 2016—Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC.
Nov. 3, 2016—Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of...
May. 26, 2016—The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.
Apr. 21, 2016—A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
Mar. 3, 2016—Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.
Dec. 10, 2015—Justin Balko, Pharm.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been named a member of the 2016 class of Pink Tie Guys by the Greater Nashville Affiliate of Susan G. Komen, a nonprofit organization dedicated to breast cancer research and patient support.
Nov. 20, 2014—A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.
Oct. 23, 2014—The grants, which total $830,000, are part of the non-profit organization’s commitment to young scientists, as well as established investigators who are searching for more effective breast cancer therapies.